Instil Bio, Inc.

Instil Bio, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its current lead program is AXN-2510/IMM2510, which it in-licensed from ImmuneOnco in 2024, and the company is still in the development and pre-commercialization phase with no approved products or product sales.

39.53

— Instil Bio, Inc.
	%
Lead product candidate	80% AXN-2510/IMM2510 is the company’s current lead immuno-oncology asset under development.
Pipeline development	10% Early-stage research and development activities for additional therapeutic assets and combinations.
Business development	10% In-licensing and acquisition of third-party oncology assets to expand the pipeline.

Instil Bio does not currently have commercial customers because it has no approved products and no product sales...

Licensors and asset sellersprimary
Biotech partners that provide in-licensed or acquired oncology assets, such as ImmuneOnco for AXN-2510/IMM2510.
Clinical development partnersprimary
Contract manufacturers, testing labs, and trial sites that support preclinical and clinical development.
Future oncology treatment centersemerging
Hospitals and specialist centers that would buy approved therapies if the company reaches commercialization.

Instil Bio is headquartered in the United States and expects future commercialization efforts to be centered there if...

•Headquartered in the United States
•Future sales and marketing infrastructure expected in the U.S.
•Relies on a third-party CDMO in China for clinical supply
•Cross-border manufacturing adds supply and quality risk
•No disclosed country revenue because the company is pre-commercial

The company’s strategy is centered on advancing AXN-2510/IMM2510 through development while preserving flexibility to...

Advance AXN-2510/IMM2510short-term

The lead asset is the core value driver and the main path to future clinical and commercial progress.

Expand pipeline through in-licensingmedium-term

Additional assets could diversify scientific risk and create more shots on goal in oncology.

Build commercialization capabilitymedium-term

A U.S. sales and marketing organization would be needed to launch any approved product.

Instil Bio faces the typical risks of a pre-commercial biotech: continued losses, dependence on external funding, and...

critical

Clinical development failure

AXN-2510/IMM2510 may not demonstrate sufficient safety or efficacy to advance or win approval.

Scope: Lead asset AXN-2510/IMM2510
Materiality: high

high

Funding and liquidity risk

The company has no product sales and expects to need substantial capital to fund development and operations.

Scope: Operating runway and pipeline execution
Materiality: high

high

Third-party manufacturing dependence

Clinical supply relies on ImmuneOnco and its CDMO in China, reducing control over quality, timing, and cost.

Scope: Supply chain and clinical trial continuity
Materiality: high

medium

Commercialization execution risk

The company has no sales or marketing infrastructure and would need to build one or partner externally.

Scope: Future launch readiness
Materiality: medium

medium

Intellectual property and competition risk

Biotech competitors may develop similar therapies or challenge patent protection.

Scope: Pipeline value and exclusivity
Materiality: medium

Restructuring and impairment charges

Tarzana facility impairment and other restructuring costs

Derivative fair value accounting

Other income (expense), net

Lease and asset impairment accounting

Balance sheet carrying values and restructuring expense

Foreign currency translation and transaction effects

Non-operating income/expense

Instil Bio, Inc.

Clinical development failure

Funding and liquidity risk

Third-party manufacturing dependence

Commercialization execution risk

Intellectual property and competition risk

Inmune Bio, Inc.

INTENSITY THERAPEUTICS, INC.

IN8BIO, INC.

MUSTANG BIO, INC.

Inhibrx Biosciences, Inc.

Imunon, Inc.